Pharmaids Pharmaceuticals Limited
Fundamental Score
Pharmaids Pharmaceuticals Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of PHARMAID across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Revenue Growth (64.31%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
7 factors identified
Below-Average Return on Equity (-16.29%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-17.43%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Profit Decline Concern (-171.97%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Weak Interest Coverage (-5.17x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Pharmaids Pharmaceuticals Limited
About PHARMAID
Business Overview
Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides contract research and manufacturing services for pharma, biotech, agro, and chemical industries in India. The company offers pharma intermediates, such as Dichloro Benzoyl nitrile, hydrazine carboximidamide 2 methane, pyridine carbonitrile,pyridine carboxylic acid, 8-chloro-10, 11-dihydro-4-aza-5H-dibenzo cycloheptene-5-one, 8-chloro-6,11-dihydro-11 cyclohepta pyridine,2-amino-5-methylthiopene-3-carbonitrile, 5-methyl-2-amino]thiophene-3-carbonitrile, 4-amino-2-methyl-10h-thiene benzodiazepine hydrochloride, 2,4-diamino-6-chloropyrimidine, hydronopol, squalene, 5-chloro-3-phenylanthranil, 2-amino-2,5-dichlorobenzophenone, 6-fluoro-3-4-piperidinyl-1,2-benzisoxazole hcl, 3-2-methyl-4H-pyrido pyrimidin-4-one, 4-n-hexyl resorcinol, triazole kopoxil, CAB-60, CABER-4, CAB-70, DTV, and avobenzone. It also provides active pharmaceuticals ingredients, including voglibose, silodosin, vitamin K2-7, UDCA, P5P, fluralaner, afoxolaner, maropitant, grapiprant, firocoxib, carprofen, loratadine, desloratadine, lamotrigine, gliclazide, and minoxidil. Pharmaids Pharmaceuticals Limited was incorporated in 1989 and is based in Bengaluru, India.
Company Details
Key Leadership
Latest News
PHARMAID Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Pharmaids Pharmaceuticals Limited (PHARMAID)?
As of 30 Jan 2026, 01:35 pm IST, Pharmaids Pharmaceuticals Limited (PHARMAID) is currently trading at ₹41.53. The stock has a market capitalization of ₹155.46 (Cr).
Is PHARMAID share price Overvalued or Undervalued?
PHARMAID is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Pharmaids Pharmaceuticals Limited share price?
Key factors influencing PHARMAID's price include its quarterly earnings growth (Sales Growth: 64.31%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Pharmaids Pharmaceuticals Limited a good stock for long-term investment?
Pharmaids Pharmaceuticals Limited shows a 5-year Profit Growth of N/A% and an ROE of -16.29%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.39 before investing.
How does Pharmaids Pharmaceuticals Limited compare with its industry peers?
Pharmaids Pharmaceuticals Limited competes with major peers in the Pharmaceuticals. Investors should compare PHARMAID's P/E of 0.00x and ROE of -16.29% against the industry averages to determine its competitive standing.
What is the P/E ratio of PHARMAID and what does it mean?
PHARMAID has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is PHARMAID performing according to Bull Run's analysis?
PHARMAID has a Bull Run fundamental score of 8/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does PHARMAID belong to?
PHARMAID operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Pharmaids Pharmaceuticals Limited.
What is Return on Equity (ROE) and why is it important for PHARMAID?
PHARMAID has an ROE of -16.29%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Pharmaids Pharmaceuticals Limited generates profits from shareholders' equity.
How is PHARMAID's debt-to-equity ratio and what does it indicate?
PHARMAID has a debt-to-equity ratio of 0.39, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is PHARMAID's dividend yield and is it a good dividend stock?
PHARMAID offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has PHARMAID grown over the past 5 years?
PHARMAID has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in PHARMAID and why does it matter?
Promoters hold 32.99% of PHARMAID shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is PHARMAID's market capitalization category?
PHARMAID has a market capitalization of ₹155 crores, placing it in the Small-cap category.
How volatile is PHARMAID stock?
PHARMAID has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for PHARMAID?
PHARMAID has a 52-week high of ₹N/A and low of ₹N/A.
What is PHARMAID's operating profit margin trend?
PHARMAID has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is PHARMAID's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 64.31% and YoY Profit Growth of -171.97%.
What is the institutional holding pattern in PHARMAID?
PHARMAID has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.